EcoDrugPlus

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSCSEG00000021068
Gene Symbol: SLC29A1
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCSEG00000016665
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSCSEG00000021606
Gene Symbol: SLC6A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSCSEG00000007621
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSCSEG00000004002
Gene Symbol: SLC6A3
3 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSCSEG00000004424
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSCSEG00000021110
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSCSEG00000009840
Gene Symbol: SLC9A3
3 Cross references
237 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSCSEG00000020271
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSCSEG00000015285
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 5

Ensembl ID : ENSCSEG00000001415
Gene Symbol: SSTR5
1 Cross references
184 Possible Orthologues:

Sphingosine Kinase 2-Like

Ensembl ID : ENSCSEG00000003527
Gene Symbol: LOC103388269
2 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).